| A novel calpastatin-based inhibitor improves postischemic neurological recovery. | |
| | |
MedLine Citation:
|
PMID: 19422795 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Calpastatin, a naturally occurring protein, is the only inhibitor that is specific for calpain. A novel blood-brain barrier (BBB)-permeant calpastatin-based calpain inhibitor, named B27-HYD, was developed and used to assess calpain's contribution to neurological dysfunction after stroke in rats. Postischemic administration of B27-HYD reduced infarct volume and neurological deficits by 35% and 44%, respectively, compared to untreated animals. We also show that the pharmacologic intervention has engaged the intended biologic target. Our data further demonstrates the potential utility of SBDP145, a signature biomarker of acute brain injury, in evaluating possible mechanisms of calpain in the pathogenesis of stroke and as an adjunct in guiding therapeutic decision making. |
| | |
Authors:
|
John Anagli; Yuxia Han; Laura Stewart; Dongmei Yang; Ashkhen Movsisyan; Kadija Abounit; Donald Seyfried |
Related Documents
:
|
19900985 - Predictable ventricular shift after focal cerebral ischaemia in rats: practical conside... 20384815 - Ubiquitin c-terminal hydrolase-l1 as a biomarker for ischemic and traumatic brain injur... 20546685 - Angiogenesis and improved cerebral blood flow in the ischemic boundary area were detect... 15755315 - The broad-spectrum cation channel blocker pinokalant (loe 908 ms) reduces brain infarct... 22292255 - The effect of hyperbaric oxygenation on the distal intestine of rats subjected to ioniz... 7120505 - Influence of spironolactone on cadmium-induced changes in hepatic and renal gluconeogen... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2009-05-05 |
Journal Detail:
|
Title: Biochemical and biophysical research communications Volume: 385 ISSN: 1090-2104 ISO Abbreviation: Biochem. Biophys. Res. Commun. Publication Date: 2009 Jul |
Date Detail:
|
Created Date: 2009-06-08 Completed Date: 2009-06-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0372516 Medline TA: Biochem Biophys Res Commun Country: United States |
Other Details:
|
Languages: eng Pagination: 94-9 Citation Subset: IM |
Affiliation:
|
Department of Pathology, Henry Ford Hospital, 1 Ford Place, 5D, Detroit, MI 48202, USA. janagli1@hfhs.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Blood-Brain Barrier / metabolism Brain / drug effects*, physiopathology Calcium-Binding Proteins / administration & dosage, therapeutic use Calpain / administration & dosage, antagonists & inhibitors, metabolism, therapeutic use* Cerebral Infarction / drug therapy*, physiopathology Cysteine Proteinase Inhibitors / administration & dosage, metabolism, therapeutic use* Disease Models, Animal Male Peptide Fragments / administration & dosage, metabolism, therapeutic use* Rats Rats, Wistar Spectrin / metabolism |
| Grant Support | |
ID/Acronym/Agency:
|
NS058581-01/NS/NINDS NIH HHS; R01 NS39075/NS/NINDS NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/B27-HYD peptide; 0/Calcium-Binding Proteins; 0/Cysteine Proteinase Inhibitors; 0/Peptide Fragments; 12634-43-4/Spectrin; 79079-11-1/calpastatin; EC 3.4.22.-/Calpain |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: SUMO modification modulates the activity of calpain-2.
Next Document: The importance of an extra loop in the B-domain of an alpha-amylase from B. stearothermophilus US100...